Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Dean Y. Li / Moderna

Dean Y. Li & Moderna

1 shared events · Importance 3 · Last updated Aug 19, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
63
Tech
Moderna Merck mRNA melanoma vaccine trial success
Dean Y. Li: As President of Merck Research Laboratories, Li commented on the potential of adjuvant therapy, supporting the scientific rationale.
Moderna: Moderna is the developer of the mRNA vaccine and the primary beneficiary, with its stock surging over 120% and market cap increasing by nearly $40 billion. The trial success validates its mRNA platform beyond COVID-19 and could lead to a new revenue stream.
Aug 19, 2026 · 102 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Dean Y. Li and Moderna interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.